These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 21522056)

  • 41. Repeated administration of piribedil induces less dyskinesia than L-dopa in MPTP-treated common marmosets: a behavioural and biochemical investigation.
    Smith LA; Tel BC; Jackson MJ; Hansard MJ; Braceras R; Bonhomme C; Chezaubernard C; Del Signore S; Rose S; Jenner P
    Mov Disord; 2002 Sep; 17(5):887-901. PubMed ID: 12360537
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Motor response to a dopamine D3 receptor preferring agonist compared to apomorphine in levodopa-primed 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine monkeys.
    Blanchet PJ; Konitsiotis S; Chase TN
    J Pharmacol Exp Ther; 1997 Nov; 283(2):794-9. PubMed ID: 9353400
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Examination of the metabolite hydroxybupropion in the reinforcing and aversive stimulus effects of nicotine in rats.
    Malcolm E; Carroll FI; Blough B; Damaj MI; Shoaib M
    Psychopharmacology (Berl); 2015 Aug; 232(15):2763-71. PubMed ID: 25761841
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Development and validation of a high-throughput stereoselective LC-MS/MS assay for bupropion, hydroxybupropion, erythrohydrobupropion, and threohydrobupropion in human plasma.
    Teitelbaum AM; Flaker AM; Kharasch ED
    J Chromatogr B Analyt Technol Biomed Life Sci; 2016 Apr; 1017-1018():101-113. PubMed ID: 26963497
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Bupropion and bupropion analogs as treatments for CNS disorders.
    Carroll FI; Blough BE; Mascarella SW; Navarro HA; Lukas RJ; Damaj MI
    Adv Pharmacol; 2014; 69():177-216. PubMed ID: 24484978
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Serum concentrations of hydroxybupropion for dose optimization of depressed patients treated with bupropion.
    Laib AK; Brünen S; Pfeifer P; Vincent P; Hiemke C
    Ther Drug Monit; 2014 Aug; 36(4):473-9. PubMed ID: 24452068
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Nitric oxide synthase inhibition and MPTP-induced toxicity in the common marmoset.
    Mackenzie GM; Jackson MJ; Jenner P; Marsden CD
    Synapse; 1997 Jul; 26(3):301-16. PubMed ID: 9183819
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Stereoselective Glucuronidation of Bupropion Metabolites In Vitro and In Vivo.
    Gufford BT; Lu JB; Metzger IF; Jones DR; Desta Z
    Drug Metab Dispos; 2016 Apr; 44(4):544-53. PubMed ID: 26802129
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The competitive NMDA antagonist CGP40.116 enhances L-dopa response in MPTP-treated marmosets.
    Wüllner U; Kupsch A; Arnold G; Renner P; Scheid C; Scheid R; Oertel W; Klockgether T
    Neuropharmacology; 1992 Jul; 31(7):713-5. PubMed ID: 1357577
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Chiral Plasma Pharmacokinetics and Urinary Excretion of Bupropion and Metabolites in Healthy Volunteers.
    Masters AR; Gufford BT; Lu JB; Metzger IF; Jones DR; Desta Z
    J Pharmacol Exp Ther; 2016 Aug; 358(2):230-8. PubMed ID: 27255113
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Bupropion and its main metabolite reverse nicotine chronic tolerance in the mouse.
    Grabus SD; Carroll FI; Damaj MI
    Nicotine Tob Res; 2012 Nov; 14(11):1356-61. PubMed ID: 22589419
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Comparison of In Vitro Stereoselective Metabolism of Bupropion in Human, Monkey, Rat, and Mouse Liver Microsomes.
    Bhattacharya C; Kirby D; Van Stipdonk M; Stratford RE
    Eur J Drug Metab Pharmacokinet; 2019 Apr; 44(2):261-274. PubMed ID: 30298475
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Stereoselective reversal of MPTP-induced parkinsonism in the marmoset after dermal application of N-0437.
    Löschmann PA; Chong PN; Nomoto M; Tepper PG; Horn AS; Jenner P; Marsden CD
    Eur J Pharmacol; 1989 Aug; 166(3):373-80. PubMed ID: 2572426
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Chirality and neuropsychiatric drugs: an update on stereoselective disposition and clinical pharmacokinetics of bupropion.
    Dash RP; Rais R; Srinivas NR
    Xenobiotica; 2018 Sep; 48(9):945-957. PubMed ID: 28876959
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Behavioral and biochemical investigations of bupropion metabolites.
    Bondarev ML; Bondareva TS; Young R; Glennon RA
    Eur J Pharmacol; 2003 Aug; 474(1):85-93. PubMed ID: 12909199
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Synthesis and characterization of in vitro and in vivo profiles of hydroxybupropion analogues: aids to smoking cessation.
    Lukas RJ; Muresan AZ; Damaj MI; Blough BE; Huang X; Navarro HA; Mascarella SW; Eaton JB; Marxer-Miller SK; Carroll FI
    J Med Chem; 2010 Jun; 53(12):4731-48. PubMed ID: 20509659
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Antiparkinsonian activity of some 9-N-, O-, S- and C-derivatives of 3-methyl-6-(prop-1-en-2-yl)cyclohex-3-ene-1,2-diol.
    Ardashov OV; Pavlova AV; Korchagina DV; Volcho KP; Tolstikova TG; Salakhutdinov NF
    Bioorg Med Chem; 2013 Mar; 21(5):1082-7. PubMed ID: 23375447
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Development of a Rat Plasma and Brain Extracellular Fluid Pharmacokinetic Model for Bupropion and Hydroxybupropion Based on Microdialysis Sampling, and Application to Predict Human Brain Concentrations.
    Cremers TI; Flik G; Folgering JH; Rollema H; Stratford RE
    Drug Metab Dispos; 2016 May; 44(5):624-33. PubMed ID: 26916207
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Characterization of the Stereoselective Disposition of Bupropion and Its Metabolites in Rat Plasma and Brain.
    Bhattacharya CS; Masters AR; Bach C; Sinn AL; Trowbridge MA; Stratford RE
    Eur J Drug Metab Pharmacokinet; 2023 Mar; 48(2):171-187. PubMed ID: 36823342
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Subtherapeutic bupropion and hydroxybupropion serum concentrations in a patient with CYP2C19*1/*17 genotype suggesting a rapid metabolizer status.
    Gaebler AJ; Schneider KL; Stingl JC; Paulzen M
    Pharmacogenomics J; 2020 Dec; 20(6):840-844. PubMed ID: 32475982
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.